publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
Pexidartinib
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
Valemetostat
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
T-DXd
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
T-DXd
Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study
Dato-DXd
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development
HER3-DXd
Changes in HER3 expression profiles between primary and recurrent gynecological cancers
T-DXd
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
Quizartinib
Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QUANTUM-R trial
T-DXd
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
HER3-DXd
Current and emerging treatment options for patients with metastatic EGFR-mutated non-small cell lung cancer after progression on osimertinib and platinum-based chemotherapy: A podcast discussion